Cardiovascular disease is a comorbidity that puts individuals at higher risk for developing COVID-19 and experiencing post-infection complications. This program describes the impact of COVID-19 in people with pre-existing cardiovascular disease, the relationship between COVID-19 and cardiovascular complications, and NACI recommendations for the COVID-19 primary series and COVID-19 vaccine booster doses.
Note: This expert brief was recorded on May 4th, 2023.
This program has received funding from Moderna Biopharm Canada Inc.